ARTELO BIOSCIENCES, INC.

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1 in the pre-IPO sequence.

2026-04-07 · 0001640334-26-000670

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

First tracked pre-IPO filing for this issuer.

Artelo Biosciences, Inc. filed a Notice of Effectiveness for its S-1 registration statement on March 30, 2026, following a prior request to withdraw its earlier S-1 filing (File No. 333-294506) on March 27, 2026. The company confirmed it does not intend to proceed with the contemplated securities offering and stated no securities were issued or sold under the withdrawn registration.

2026-03-30 · 9999999995-26-001002

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows S-1 and ends the active registration process.

Artelo Biosciences, Inc. has submitted a Form RW to withdraw its previously effective Registration Statement on Form S-1 (File No. 333-294506), which was filed on March 20, 2026. The company confirms no securities were issued or sold under the registration and cites its decision not to pursue the contemplated offering. The withdrawal request includes a request to credit fees paid to the SEC for future use.

2026-03-27 · 0001640334-26-000558

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

Artelo Biosciences, Inc. has filed an effective registration statement (EFFECT) for its IPO, offering up to 1,641,587 shares of common stock, pre-funded warrants, and placement agent warrants. The offering is on a best-efforts basis with an assumed public price of $7.31 per share, based on the company's recent Nasdaq closing price. The company engaged Craft Capital Management LLC as the exclusive placement agent, with fees including 7% of gross proceeds and 4% in placement agent warrants. The offering is expected to close by March 31, 2026, with no minimum offering requirement.

2026-03-25 · 9999999995-26-000932

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows S-1/A in the pre-IPO sequence.

Artelo Biosciences, Inc. filed an S-1 registration statement for the resale of up to 4,273,519 shares of common stock by Square Gate Capital Master Fund, LLC - Series 5 under an Equity Purchase Agreement. The filing outlines two components: commitment shares (including pre-funded warrants) and put shares issued at a discount to the market price. Unlike the previous S-1/A, which focused on an initial offering of 1.6 million shares and pre-funded warrants, this filing emphasizes the resale structure and potential $50 million in gross proceeds from company-led sales. The company is not directly involved in the resale but may benefit from future sales under the ELOC Purchase Agreement.

2026-03-24 · 0001640334-26-000543

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Artelo Biosciences, Inc. is conducting a primary offering of 1,641,587 shares of common stock, pre-funded warrants, and placement agent warrants, differing from the previous S-1 which focused on a resale offering by Square Gate Capital. The current filing includes detailed terms for the offering, including a public price of $7.31 per share, placement agent fees, and warrants. The company also highlights risks related to the lack of a market for pre-funded warrants and uncertainty in offering proceeds.

2026-03-24 · 0001640334-26-000540

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Artelo Biosciences, Inc. is conducting an IPO offering up to 1,641,587 shares of common stock at an assumed public price of $7.31, with pre-funded warrants and placement agent warrants. The offering is subject to a closing date of March 31, 2026, and includes provisions for delivery versus payment. The company emphasizes risks related to market volatility, uncertain proceeds, and lack of liquidity for warrants.

2026-03-23 · 0001640334-26-000515

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS in the pre-IPO sequence.

Artelo Biosciences, Inc. is conducting an IPO offering up to 1,641,587 shares of common stock at an assumed public price of $7.31, along with pre-funded warrants and placement agent warrants. The offering is on a best-efforts basis with no minimum requirements, and the company has engaged Craft Capital Management LLC as the exclusive placement agent. The filing highlights potential dilution, lack of established markets for pre-funded warrants, and risks related to the offering's pricing and structure.

2026-03-20 · 0001640334-26-000502

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after EFFECT.

Artelo Biosciences, Inc. filed a draft registration statement (DRS) for a potential IPO, registering up to 29,293,631 shares of common stock for resale by Square Gate Capital Master Fund, LLC - Series 5. The company is not receiving proceeds from the resale but may access up to $50 million via the ELOC Purchase Agreement. The stock is listed on Nasdaq under 'ARTL,' with a recent closing price of $1.14. The filing includes risk factors, a plan of distribution, and details about the ELOC agreement terms.

2026-03-09 · 0001640334-26-000403

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

Artelo Biosciences, Inc. has filed an S-1 registration statement for the resale of up to 899,972 shares of common stock by selling securityholders. The shares include those from convertible notes, $6.24 warrants, and $3.40 warrants. The company is not receiving proceeds from the resale but may receive net proceeds from warrant exercises. A 1-for-6 reverse stock split effective June 13, 2025, adjusted all share and per-share amounts. The filing includes details about the company's capital structure, risk factors, and distribution plans.

2025-12-02 · 9999999995-25-003484

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS in the pre-IPO sequence.

Artelo Biosciences, Inc. filed an S-1 registration statement for the resale of up to 899,972 shares of common stock by selling securityholders, including shares from convertible notes and warrants issued in private placements. The filing includes a 1-for-6 reverse stock split adjustment effective June 13, 2025, and notes that the company will not receive proceeds from the resale but may receive net proceeds from warrant exercises. The company is a smaller reporting company with risks related to its high-risk investment profile and potential SEC scrutiny of selling securityholders as underwriters.

2025-11-17 · 0001640334-25-002154

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after EFFECT.

Artelo Biosciences, Inc. has submitted a confidential draft registration statement (DRS) for an upcoming IPO, which remains non-public and subject to change. The filing outlines an offering of up to [ ] units, each comprising common stock, pre-funded warrants, and warrants, with an assumed public offering price based on recent Nasdaq trading data. The company intends to use a placement agent for a best-efforts offering, with proceeds dependent on investor demand. The registration statement is not yet effective and requires further amendments to become publicly effective.

2025-09-29 · 0001640334-25-001740

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

ARTELO BIOSCIENCES, INC. has filed an effective S-1 registration statement for the resale of up to 920,092 shares of common stock by selling securityholders. The offering includes common stock, pre-funded warrants, and warrants with exercise prices of $5.82 and $10.00. The company underwent a 1-for-6 reverse stock split effective June 13, 2025, adjusting all share and per-share amounts. The registration does not involve direct proceeds to the company, except from warrant exercises. The filing references a private placement priced on June 24, 2025, and incorporates risk factors related to market volatility, regulatory changes, and reliance on third-party collaborations.

2025-07-17 · 9999999995-25-002274

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Artelo Biosciences, Inc. has filed an S-1 registration statement to register up to 920,092 shares of common stock for resale by selling securityholders. The shares include common stock, pre-funded warrants, and warrants with exercise prices of $5.82 and $10.00. The company did not receive proceeds from the resale but may receive proceeds from warrant exercises. A 1-for-6 reverse stock split was effective June 13, 2025, adjusting all share numbers. The company is a smaller reporting company and trades on Nasdaq under 'ARTL' with a recent closing price of $28.50.

2025-07-11 · 0001640334-25-001190

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Artelo Biosciences, Inc. received effectiveness for its S-3 registration statement, transitioning from the S-1 filing used for its initial public offering. The current filing indicates the company is registering additional securities, likely for a secondary offering, following its earlier IPO-related S-1 submission.

2023-07-14 · 9999999995-23-002100

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

Artelo Biosciences, Inc. filed a Notice of Effectiveness for its S-1 registration statement, confirming the effectiveness of its $15 million common stock offering. The offering involves up to 15,000,000 shares of common stock registered under the Securities Act of 1933, with Lincoln Park Capital Fund, LLC acting as the selling stockholder. The company will not receive proceeds from the sale, and the shares are quoted on the Nasdaq Capital Market under the symbol 'ARTL.'

2022-05-31 · 9999999995-22-001644

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Artelo Biosciences, Inc. is registering 15,000,000 shares of common stock through a selling stockholder, Lincoln Park Capital Fund, LLC. The offering is part of a delayed registration statement, with no proceeds going to the company. The company operates as a smaller reporting company and faces significant risks in its clinical development and commercialization efforts.

2022-05-16 · 0001640334-22-001028

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Artelo Biosciences, Inc. filed a Notice of Effectiveness for its securities offering, confirming the registration of 8,800,000 units consisting of common stock and warrants. The offering, underwritten by Ladenburg Thalmann & Co. Inc., includes a public price of $0.75 per unit, with proceeds totaling $6.6 million. The filing highlights the company's clinical-stage pipeline, including programs targeting the endocannabinoid system and FABP5, while noting uncertainties due to the COVID-19 pandemic's impact on clinical timelines.

2021-01-21 · 9999999995-21-000207

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

Artelo Biosciences, Inc. received SEC effectiveness for its registration statement on January 21, 2021. The filing indicates the company's securities may now be publicly offered, with the registration statement identified by a new file number (333-249083) compared to a prior filing (333-230658).

2021-01-21 · 9999999995-21-000211

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Artelo Biosciences, Inc. is offering 8,800,000 units, each consisting of one share of common stock and one warrant to purchase a share at $0.75. The offering is underwritten on a firm commitment basis, with proceeds estimated at $6.07 million. The company focuses on developing therapies targeting the endocannabinoid system, including programs for cancer-related anorexia, prostate/breast cancer, and inflammatory conditions. Clinical trials face uncertainties due to the COVID-19 pandemic, and the company has limited financial resources.

2020-10-13 · 0001640334-20-002532

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Artelo Biosciences, Inc. filed a Notice of Effectiveness for its Form S-1 registration statement on October 8, 2020, indicating the filing became effective. The current filing represents Amendment No. 2 to the S-1, which was an exhibits-only submission. Key components include Part II of the registration statement, covering expenses, indemnification provisions, and recent unregistered securities sales. The prospectus itself remained unchanged from prior filings.

2020-10-08 · 9999999995-20-002794

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Artelo Biosciences, Inc. filed an S-1/A amendment to its registration statement on October 8, 2020, primarily as an exhibits-only update. The amendment revised Exhibit 5.1 and added Exhibit 5.2, with the prospectus remaining unchanged. The filing reflects ongoing preparatory steps for the IPO, including legal opinions and offering documentation.

2020-10-08 · 0001640334-20-002503

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Artelo Biosciences, Inc. filed Amendment No. 2 to its S-1 registration statement, primarily as an exhibits-only filing. The prospectus remains unchanged, with updates focused on Part II disclosures, including detailed information on recent unregistered securities offerings, indemnification provisions, and registration fees. The filing emphasizes private placements of common stock and warrants, with specific terms for Series A through E offerings and additional shares issued to directors and consultants.

2020-10-07 · 0001640334-20-002484

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments targeting endogenous signaling pathways, including the endocannabinoid system. The company is advancing three product candidates: ART27.13 for cancer-related anorexia, ART26.12 as a FABP5 inhibitor, and ART12.11 as a CBD cocrystal. The current S-1/A filing outlines an offering of 6,395,348 units comprising common stock and warrants, with an assumed public offering price of $0.86 per unit. The filing highlights delays in clinical timelines due to the COVID-19 pandemic and updates to warrant terms, including exercise pricing and exercisability conditions.

2020-10-06 · 0001640334-20-002471

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

First tracked pre-IPO filing for this issuer.

2020-10-06 · 0001640334-20-002473

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments targeting the endocannabinoid system (ECS). The current S-1 filing relates to an IPO offering units consisting of common stock and warrants, with a proposed maximum offering price of $4,000,000. The company is advancing multiple product candidates, including ART27.13 for cancer-related anorexia, ART26.12 as a synthetic endocannabinoid modulator, and ART12.11, a CBD cocrystal formulation. The filing highlights risks related to clinical trial delays, regulatory approvals, competition, and the impact of the COVID-19 pandemic on timelines.

2020-09-28 · 0001640334-20-002415

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Artelo Biosciences, Inc.'s registration statement became effective on April 10, 2020, under the S-3 form. The current filing reflects an updated effectiveness date compared to the previous S-3 filing in February 2020, with no visible substantive changes in the disclosed information.

2020-04-10 · 9999999995-20-000720

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

Artelo Biosciences, Inc. filed a Notice of Effectiveness for its S-3 registration statement, which became effective on February 3, 2020. This filing follows a prior effectiveness notice dated December 20, 2019, for the same company and form type, indicating the continuation of the company's shelf registration process under the Securities Act of 1933.

2020-02-03 · 9999999995-20-000214

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows EFFECT and marks the registration effective.

The current filing confirms the effectiveness of Artelo Biosciences' S-3 registration statement, following a previous 424B4 prospectus for a public offering of 1,300,813 units. The units consist of common stock and warrants, with an offering price of $6.15 per unit. The filing aligns with prior disclosures regarding the company's clinical-stage biopharmaceutical focus on endocannabinoid system modulation, including CBD cocrystal and other pipeline candidates.

2019-12-20 · 9999999995-19-002888

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B4 and marks the registration effective.

The filing for Artelo Biosciences, Inc. became effective on December 20, 2019, for an S-3 registration statement. The current filing replaces a previous S-3 registration with a new file number, indicating a revised or updated securities offering registration.

2019-12-20 · 9999999995-19-002879

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Artelo Biosciences, Inc. is conducting a firm commitment public offering of 1,300,813 units, each consisting of one share of common stock and one warrant. The offering price is $6.15 per unit, with proceeds totaling $7.36 million. The company, an emerging growth company under the JOBS Act, has completed a 1-for-8 reverse stock split. Its common stock and warrants are now listed on Nasdaq, and the offering includes underwriting discounts and potential over-allotment options. The prospectus highlights risks related to clinical development, regulatory approval, and capital requirements.

2019-06-25 · 0001640334-19-001225

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

First tracked pre-IPO filing for this issuer.

Artelo Biosciences, Inc. filed a Form 8-A12B to register its common stock and warrants under Section 12(b) of the Securities Exchange Act of 1934, incorporating by reference the securities description from its earlier S-1 registration statement. The filing focuses on the registration of securities for trading on The Nasdaq Stock Market LLC, without providing new details beyond the previously disclosed information.

2019-06-21 · 0001640334-19-001191

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

Artelo Biosciences, Inc. filed an S-1 registration statement for an IPO, which became effective on June 20, 2019. The offering includes 1,388,888 units consisting of common stock and warrants, with a public offering price of $7.56 per unit. The company plans to use proceeds for operational and developmental purposes. It is an emerging growth company under the JOBS Act and has implemented a reverse stock split. The offering includes underwriter warrants and potential over-allotment options.

2019-06-20 · 9999999995-19-001390

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Artelo Biosciences, Inc. filed an S-1/A amendment to its registration statement, primarily consisting of exhibits, Part II disclosures, and signature pages. The filing includes details on securities registration, expenses, indemnification provisions, and recent unregistered sales. The company is seeking to register shares for public offering, with prior private placements and warrants issued to accredited investors.

2019-06-20 · 0001640334-19-001174

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Artelo Biosciences, Inc. is offering 1,388,888 units consisting of common stock and warrants to raise up to $11.5 million. The company focuses on developing cannabinoid-based therapies, including a CBD cocrystal with improved pharmaceutical properties. Key programs include ART27.13 for cancer-related anorexia and ART26.12 as an endocannabinoid modulator. The filing highlights clinical trials, patent protections, and the company's status as an emerging growth company.

2019-06-10 · 0001640334-19-001091

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for the endocannabinoid system (ECS), including a proprietary CBD cocrystal (ART12.11) and two in-licensed programs: ART27.13 for cancer-related anorexia and ART26.12 as an FABP5 inhibitor for cancer. The company is offering 1,388,888 shares of common stock and warrants, aiming to list on Nasdaq. The filing highlights its pipeline, intellectual property, and regulatory strategies, with a focus on overcoming challenges in cannabinoid-based drug development.

2019-05-31 · 0001640334-19-001007

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for the endocannabinoid system (ECS), including a proprietary CBD cocrystal (ART12.11) and two in-licensed programs: ART27.13 for cancer-related anorexia and ART26.12 for FABP5 inhibition. The S-1/A filing details an IPO offering of 1,388,888 shares of common stock and warrants, with a proposed maximum offering price of $11.5M for common stock and $12.075M for underlying shares. The company highlights its pipeline progress, including Phase 1b/2a trials for ART27.13 and late pre-clinical stages for ART26.12, alongside intellectual property claims for its CBD cocrystal.

2019-05-29 · 0001640334-19-001003

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Artelo Biosciences, Inc. filed an S-1 registration statement for an IPO, offering up to $15.88 million in common stock and warrants. The company is a clinical-stage biopharmaceutical firm focused on endocannabinoid system (ECS) modulation, with pipeline candidates including a CBD cocrystal (ART12.11), ART27.13 for cancer-related anorexia, and ART26.12 as an FABP5 inhibitor. The offering includes placement agent warrants and aims to list on Nasdaq, with proceeds intended for clinical trials, research, and general operations. The company is an emerging growth company under the JOBS Act.

2019-04-01 · 0001640334-19-000498

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1 and marks the registration effective.

Artelo Biosciences, Inc. filed an S-1 registration statement that became effective on October 5, 2018, allowing the company to offer 2,426,424 shares of common stock through selling stockholders. The shares include 1,213,212 warrants exercisable for common stock and 1,213,212 previously issued shares. The company will not receive proceeds from the sale of these shares, only from warrant exercises. The stock is quoted on the OTCQB under the symbol ARTL, with a closing bid price of $1.60 as of September 26, 2018.

2018-10-05 · 9999999995-18-002562

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Artelo Biosciences, Inc. filed an S-1 registration statement to offer 2,426,424 shares of common stock, including shares from private placements and warrants. The company, formerly focused on online advertising, rebranded to pursue cannabinoid-based therapies. Key developments include a license agreement with NEOMED for a compound, subsidiary formations in Ireland and England, and a private placement in July 2017. The filing emphasizes risks related to clinical trials, reliance on a single compound, and speculative nature of biotech investments.

2018-09-27 · 0001640334-18-001830

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

The SEC has declared the registration statement for Artelo Biosciences, Inc.'s Form S-1 effective as of May 29, 2018. The filing relates to 5,922,564 shares of common stock, including 2,751,282 shares from warrant exercises and 3,171,282 shares from prior private placements. The shares will be sold by selling stockholders at $0.65 per share until the company's stock is quoted on the OTC Bulletin Board, after which sales will occur at market prices. The company will not receive proceeds from these sales. The stock is currently quoted on the OTC Pink under the symbol ARTL.

2018-05-29 · 9999999995-18-001358

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Artelo Biosciences, Inc. is a biotechnology company focused on developing cannabinoid-based therapeutic treatments. The company has undergone multiple name changes, including from Knight Knox Development Corp. to Reactive Medical, Inc., and finally to Artelo Biosciences, Inc. It has established subsidiaries in Ireland and England to manage European operations and secured exclusive licenses for drug development from NEOMED and Stony Brook University. The current filing relates to a public offering of 5,922,564 shares of common stock, including shares from private placements and warrants, with proceeds not directly benefiting the company.

2018-05-14 · 0001640334-18-000945

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Artelo Biosciences, Inc. (formerly Reactive Medical, Inc.) is a biotechnology company focused on developing cannabinoid-based therapeutic treatments. The company has undergone multiple corporate changes, including name changes, leadership transitions, and strategic partnerships. Key activities include licensing agreements for drug development, private placements, and expansion into European operations. The filing relates to a registered offering of 5,922,564 shares of common stock, including shares from private placements and warrants, with no proceeds to the company from secondary sales.

2018-04-17 · 0001640334-18-000750

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Artelo Biosciences, Inc. filed an S-1/A registration statement to offer 5,922,564 shares of common stock, including 3,171,282 shares from private placements and 2,751,282 shares via warrant exercises. The company, formerly Reactive Medical, Inc., rebranded to focus on cannabinoid-based therapies and drug development. Key corporate changes include leadership transitions, subsidiary formations in Ireland and England, and a license agreement with Analog Biosciences for cannabinoid research. The offering is structured to allow selling stockholders to sell shares at $0.65 per share, with no proceeds to the company from stock sales.

2018-03-21 · 0001640334-18-000507

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows EFFECT in the pre-IPO sequence.

Artelo Biosciences, Inc. (formerly Knight Knox Development Corp.) transitioned from an online business model to a biosciences-focused company, undergoing multiple name changes and leadership shifts. The current S-1 filing relates to a public offering of 5,618,162 shares of common stock, including shares from private placements and warrants, with no proceeds to the company. The company focuses on cannabinoid-based therapies and has entered into licensing agreements, including with NEOMED, while facing risks related to regulatory approval and market speculation.

2018-01-29 · 0001640334-18-000191

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows S-1/A and marks the registration effective.

The filing marks the effectiveness of Knight Knox Development Corp.'s S-1 registration statement for an initial public offering (IPO) of 8,000,000 shares of common stock at $0.01 per share. The company, a development-stage entity with minimal operations, seeks to raise up to $80,000. The offering is self-underwritten, with no minimum sales requirement, and shares will be sold by the sole officer. The company is a shell entity with no public market for its stock, and there is no assurance of OTCBB quotation. Auditors expressed substantial doubt about the company's ability to continue as a going concern.

2015-01-28 · 9999999995-15-000221

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Knight Knox Development Corp. is a development-stage company with minimal operations seeking to raise $80,000 through an initial public offering of 8,000,000 shares of common stock at $0.01 per share. The company is a shell entity with no established trading market, and there is no guarantee of liquidity or successful funding. Auditors have expressed substantial doubt about its ability to continue as a going concern. The offering is self-underwritten with no minimum purchase requirements, and proceeds will be used for general corporate purposes.

2015-01-23 · 0001557240-15-000043

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Artelo Biosciences, Inc. (formerly Knight Knox Development Corp.) is conducting an initial public offering (IPO) to register 8,000,000 shares of common stock at $0.01 per share. The company, a development-stage entity with minimal operations, is self-underwriting the offering on a 'best efforts' basis. Proceeds will be used for general corporate purposes, with no minimum fundraising target. The offering carries significant risks, including illiquidity, lack of a public market, and auditor doubts about the company's ability to continue as a going concern.

2014-12-24 · 0001557240-14-000797

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

First tracked pre-IPO filing for this issuer.

Knight Knox Development Corp. is a development-stage company with minimal operational activity seeking to raise $80,000 through an initial public offering (IPO) of 8,000,000 shares of common stock at $0.01 per share. The company has no existing public market for its securities, and proceeds will be used for general operations. Its independent auditors have expressed substantial doubt about its ability to continue as a going concern. The offering is self-underwritten by the sole officer/director, with no guaranteed funding or market liquidity. The company qualifies as an emerging growth company under the JOBS Act.

2014-10-08 · 0001557240-14-000578

ARTELO BIOSCIENCES, INC.

Filing Timeline

8 comparable deals

Recent News